NASDAQ$ATEC
Alphatec Holdings Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
ATEC reported first quarter financial results with U.S. revenue growth accelerating to 50%.
Alphatec Holdings, Inc. announced financial results for the quarter ended March 31, 2021. Total revenue was $44.1 million, with U.S. revenue reaching $43.7 million, reflecting a 50% growth. The company anticipates total revenue for the full year 2021 to be approximately $190 million.
- U.S. revenue growth accelerated to 50%.
- Revenue growth averaged approximately 33% over the past eight quarters.
- New products contributed to 77% of U.S. revenue, up from 56% in Q1 2020.
- Sales network transformation delivered 60% year-over-year revenue growth from strategic distribution.
Headline financials
Revenue & EPS history
Alphatec · Revenue · Quarterly
$44.1M
Revenue by segment
Alphatec · $104M total across 1 segment · Q3 2023
- Surgical Revenue$104M—100.0%
Forward guidance
The Company expects total revenue for the fiscal year ended December 31, 2021, to approximate $190 million, which includes U.S. revenue of approximately $188 million. Revenue guidance reflects expected U.S. revenue growth of roughly 33% compared to 2020, driven by continued launches of novel procedures, products, and the revitalization of the Company’s distribution network. Total revenue guidance contemplates the anticipated wind-down of the Company’s international supply agreement on August 31, 2021.
Tailwinds
- Continued launches of novel procedures and products.
- Revitalization of the Company’s distribution network.
- Expected U.S. revenue growth of roughly 33% compared to 2020.
- Anticipated positive impact of EOS imaging acquisition.
- Focus on improving the clinical experience in spine.
Headwinds
- Anticipated wind-down of the Company’s international supply agreement on August 31, 2021.
- Impact of COVID-19 pandemic on the Company's business and the economy.
- Uncertainty of success in developing new products or products currently in the Company’s pipeline.
- Uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products.
- Failure to achieve acceptance of the Company’s products by the surgeon community.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-1.5%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-0.1%
Avg return
30 days after
45%
29 / 64 earnings
Positive
+44.8%
Q3 2024
Best reaction
-43.2%
Q2 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -27.1% | -23.3% | |
| Q4 2025 | +0.5% | -3.3% | -21.5% | |
| Q3 2025 | -0.8% | +17.8% | +36.7% | |
| Q1 2025 | +2.4% | +2.2% | +2.2% | |
| Q4 2024 | +9.6% | +6.1% | -7.9% | |
| Q3 2024 | +44.8% | +54.2% | +93.4% | |
| Q2 2024 | -32.8% | -33.7% | -30.2% | |
| Q1 2024 | -20.2% | -13.3% | -22.7% | |
| Q4 2023 | -7.4% | -11.1% | -8.6% | |
| Q3 2023 | +4.7% | -1.5% | +20.8% | |
| Q2 2023 | -7.1% | -10.4% | -5.2% | |
| Q1 2023 | +3.1% | +3.8% | +4.5% | |
| Q4 2022 | +1.6% | +7.9% | +6.3% | |
| Q3 2022 | -1.5% | -1.4% | +9.5% | |
| Q2 2022 | -0.2% | -3.8% | -10.9% | |
| Q1 2022 | -16.1% | -27.7% | -34.0% | |
| Q4 2021 | +3.1% | +3.4% | +4.4% | |
| Q3 2021 | -2.2% | -8.2% | -18.7% | |
| Q2 2021 | +2.4% | -5.8% | -0.2% | |
| Q1 2021 | -2.0% | -9.1% | -8.3% | |
| Q4 2020 | -7.6% | +4.2% | -2.1% | |
| Q3 2020 | +9.4% | +4.7% | +22.1% | |
| Q2 2020 | +21.8% | +5.6% | +3.1% | |
| Q1 2020 | -8.0% | -13.9% | +5.7% | |
| Q4 2019 | -8.4% | -20.8% | -47.2% | |
| Q3 2019 | +15.2% | +16.1% | +18.1% | |
| Q2 2019 | +9.3% | +8.5% | +26.2% | |
| Q1 2019 | +5.4% | +15.8% | +8.8% | |
| Q4 2018 | +14.7% | +16.6% | +22.1% | |
| Q3 2018 | -1.7% | -5.6% | -13.5% | |
| Q2 2018 | +4.7% | +15.0% | +28.1% | |
| Q1 2018 | -2.0% | -0.9% | -1.1% | |
| Q4 2017 | +0.9% | -5.0% | +1.2% | |
| Q3 2017 | -0.8% | -0.6% | -30.5% | |
| Q2 2017 | +2.4% | +2.4% | +40.2% | |
| Q1 2017 | +1.9% | +0.0% | -4.8% | |
| Q4 2016 | -16.0% | -27.0% | -45.8% | |
| Q3 2016 | -15.8% | -8.0% | -12.8% | |
| Q2 2016 | +2.5% | +0.0% | -6.5% | |
| Q1 2016 | -11.8% | — | — | |
| Q4 2015 | -13.8% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | -42.6% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | +7.4% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +2.3% | — | — | |
| Q4 2013 | +22.3% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | -3.9% | — | — | |
| Q1 2013 | -3.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q3 2012 | -1.8% | — | — | |
| Q2 2012 | -2.5% | — | — | |
| Q1 2012 | -7.4% | — | — | |
| Q4 2011 | -0.5% | — | — | |
| Q3 2011 | -5.6% | — | — | |
| Q2 2011 | -10.4% | — | — | |
| Q1 2011 | +3.7% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | -9.6% | — | — | |
| Q2 2010 | -43.2% | — | — | |
| Q1 2010 | +6.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro